Mechanism and regulation of the SCF ubiquitination pathway  by Deshaies, Ray
Forefronts in Nephrology1186
loops involving CDK activity and transcriptional regula- REFERENCES
tion contribute to make these cell cycle positions semista- 1. Cross FR: Starting the cell cycle: What’s the point? Curr Opin
Cell Biol 7:790–797, 1995ble “states.” The expression of other genes is tied in to
2. Cross F: Transcriptional regulation by a cyclin-cdk. Trends Genet
the same regulatory circuitry driving expression of these 11:209–211, 1995
3. Levine K, Tinkelenberg AH, Cross F: The CLN gene family:regulators, resulting in cell cycle regulation of genes in-
Central regulators of cell cycle Start in budding yeast. Prog Cellvolved in downstream aspects of cell cycle control. The Cycle Res 1:101–114, 1995
4. Nasmyth K: At the heart of the budding yeast cell cycle. Trendstranscriptional control of CDK regulators is not essential
Genet 12:405–412, 1996but, rather, probably serves to fine tune the biological 5. Oehlen L, Cross FR: The mating factor response pathway regu-
lates transcription of TEC1, a gene involved in pseudohyphal dif-control of the system. Control by proteolytic and other
ferentiation of Saccharomyces cerevisiae. FEBS Lett 429:83–88,inhibitory mechanisms is more central and essential for 1998
6. Oehlen L, Cross FR: The role of Cde42 in signal transductionappropriate cell cycle control.
and mating of the budding yeast Saccharomyces cerevisiae. J BiolCyclins are absolutely required for enzymatic activa- Chem 273:8556–8559, 1998
7. Oehlen L, Cross FR: Potential regulation of Ste20 function bytion of CDKs. As in all eukaryotes, budding yeast con-
the Cln1-Cdc28 and Cln2-Cdc28 cyclin-dependent protein kinases.tains multiple cyclin genes that appear to function to J Biol Chem 273:25089–25097, 1998
8. Joeung DI, Oehlen LJ, Cross FR: Cln3-associated kinase activitycontrol different cell cycle events. In order to begin disso-
in Saccharomyces cerevisiae is regulated by the mating factor path-ciating the role of cyclins as simple enzymatic activators way. Mol Cell Biol 18:433–441, 1998
9. Cross FR, Levine K: Molecular evolution allows bypass of theof CDK as distinct from roles of cyclins as specific tar-
requirement for activation loop phosphorylation of the Cdc28geting subunits, we have begun genetic approaches to cyclin-dependent kinase. Mol Cell Biol 18:2923–2931, 1998
10. Gartner A, Jovanovic A, Jeoung DI, Bourlat S, Cross FR,“protein engineering” a cyclin-independent version of
Ammerer G: Pheromone-dependent G1 cell cycle arrest requiresthe Cdc28 cyclin-dependent kinase. Thus far, the results Far1 phosphorylation, but may not involve inhibition of Cdc28-
suggest that some cell cycle events may occur simply as Cln2 kinase, in vivo. Mol Cell Biol 18:3681–3691, 1998
11. Oehlen LJ, Jeoung DI, Cross FR: Cyclin-specific START eventsa consequence of enzymatic activation of CDK, whereas and the G1-phase specificity of arrest by mating factor in budding
others may require specific targeting by cyclin. yeast. Mol Gen Genet 258:183–198, 1998
Mechanism and regulation of the SCF ubiquitination pathway
RAY DESHAIES
California Institute of Technology, Pasadena, California, USA
Entry into the S phase in budding yeast requires inacti- ize the localization, abundance, and composition of SCF
complexes in vivo. Homologues of SCF components havevation of the S-phase cyclin-dependent kinase (CDK)
inhibitor Sic1. We have shown that this is achieved via been detected in other eukaryotes, and a human Cdc53
homologue (CUL1) is able to complement a cdc53tsphosphorylation-triggered ubiquitin-dependent proteoly-
sis. During the early G1 phase, stable Sic1 prevents the mutant. Human CUL1, SKP1, and SKP2 (an F-box pro-
tein that is presumed to serve as a Cdc4-like substrateprecocious activation of S-phase–promoting CDK com-
plexes. Late in the G1 phase, newly assembled G1 cyclin/ receptor) assemble into SCF-like complexes upon ex-
pression in insect cells, but these complexes have notCDK complexes phosphorylate Sic1 (G1 cyclin/CDK
complexes are insensitive to Sic1 inhibition). Phospho- yet been shown to catalyze CDC34-dependent ubiquiti-
nation of a defined substrate. However, human CUL1Sic1 is selectively recognized by a ubiquitin ligase (E3)
complex containing Cdc53, Cdc4, and Skp1. This assem- and human SKP1 can assemble into chimeric SCF com-
plexes with yeast Cdc4, and these complexes can sustainblage has been named SCF for Skp1-Cdc53/CUL-F Box
receptor E3 complex. Upon binding to SCF, phospho- the Cdc34-dependent ubiquitination of phospho-Sic1,
confirming that the yeast and human proteins possessSic1 is extensively ubiquitinated by the Cdc34 ubiquitin-
conjugating enzyme. Coprecipitation analyses have re- similar biochemical functions. We have recently devel-
oped a biochemical assay that may allow us to identifyvealed that the Cdc4 and Skp1 subunits of SCF selectively
bind phospho-Sic1, thereby linking it to Cdc53 and substrates and/or regulators of human CUL1 complexes.
The identification of CUL1 as a component of a ubiquitinCdc34. Efforts are currently underway to further subdi-
vide the functional organization of SCF and to character- ligase complex and the availability of biochemical assays
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A transcription factor network regulating cell proliferation
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The myc proto-oncogene family is profoundly in- tion and are involved in cell proliferation and oncogene-
sis, Mad:Max heterodimers act as transcriptional repres-volved in the genesis of diverse tumor types in many
animal species, including humans. The myc genes are sors at their DNA binding sites through recruitment of
a “repression complex,” including the mSin3 A/B core-also expressed during proliferation of normal cells and
are known to be involved in cell cycle entry and apopto- pressors and histone deacetylases (HDAC1/2). The re-
pression complex recruited by Mad:Max to DNA is alsosis. Myc expression must be turned off during terminal
differentiation of a wide range of cell types. The Myc used by other transcriptional repressors, including unli-
ganded nuclear hormone receptors. It has been sug-proteins, encoded by myc family genes, are basic-helix-
loop-helix-zipper (bHLHZ) class transcription factors gested that deacetylation of histones in chromatin or
of other factors involved in transcription may lead tothat form specific heterodimers with the Max protein.
Although Myc alone does not dimerize or bind DNA, repression. Mad family proteins are expressed during
terminal differentiation of a wide variety of cell types.Myc:Max heterodimers specifically recognize DNA and
activate transcription at target genes. We have recently Targeted disruption of the mad1 gene in mice has dem-
onstrated that mad1 is required for limiting the prolifera-shown that Max also dimerizes with another group of
bHLHZ proteins: the Mad family (Fig. 1). tion of hematopoietic precursor cells. These results indi-
cate that Mad1 regulates cell cycle withdrawal duringAlthough Myc:Max heterodimers activate transcrip-
differentiation and suggest that the relative levels of Myc
versus Mad mediate a balance between cell proliferation
and terminal differentiation or apoptosis. Because Mad’s
biological effects are closely linked to its transcription
repression activity, our data indicate that Mad’s role in
cell cycle exit may involve the activity of histone deacety-
lases and possibly changes in chromatin structure.
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